KIT (CD117) — Targeted Therapies, Trials & Pipeline
Activating KIT mutations (exons 9, 11, 13, 17) drive most gastrointestinal stromal tumors and are treated with sequential tyrosine kinase inhibitors; KIT D816V drives systemic mastocytosis.
Activating KIT mutations (exons 9, 11, 13, 17) drive most gastrointestinal stromal tumors and are treated with sequential tyrosine kinase inhibitors; KIT D816V drives systemic mastocytosis.